ExodusPoint Capital Management, LP
Position in APGE — Apogee Therapeutics, Inc.
CIK 1736225
NEW YORK, NY
Position in APGE
as of Jun 30, 2026
· filed Aug 14, 2026
Position Value
$46,190
-$1,445,075 QoQ
Shares Held
348
-99.1% QoQ
Ownership
0.000%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
#243
of 285 holders
Holding Since
Sep 2025
2 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in APGE Over Time
Shares Held
Position Value (USD)
Derivatives in APGE
reported options exposure · as of Jun 30, 2026CallValue
$11,613,875
CallShares
87,500
PutValue
$0
PutShares
0
Notional value of option positions as reported on Form 13F. Calls and puts are disclosed separately and do not net against the common-share stake above.
Position in Biotechnology
Healthcare · as of Jun 30, 2026ExodusPoint Capital Management, LP holds $275,349,927 across 101 Biotechnology names. APGE ranks #100 (0.0% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | CYTK |
Cytokinetics Inc
|
249,259 | $21,234,374 | |
| 2 | BBIO |
BridgeBio Pharma, Inc.
|
224,927 | $16,752,562 | |
| 3 | ORKA |
Oruka Therapeutics, Inc.
|
148,212 | $14,105,336 | |
| 4 | VKTX |
Viking Therapeutics, Inc.
|
361,126 | $14,087,525 | |
| 5 | JAZZ |
Jazz Pharmaceuticals plc
|
53,201 | $12,819,844 | |
| 6 | NAMS |
NewAmsterdam Pharma Co N.V.
|
304,334 | $10,313,879 | |
| 7 | TGTX |
Tg Therapeutics, Inc.
|
164,513 | $9,038,344 | |
| 8 | DNLI |
Denali Therapeutics Inc.
|
336,567 | $8,656,503 |
All Filings in APGE
Export CSV
3 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $46,190 | 348 | Shares | Sole | 2026-08-14 | |
| 2026-06-30 | $11,613,875 | 87,500 | Call | Sole | 2026-08-14 | |
| 2025-09-30 | $1,491,265 | 37,535 | Shares | Sole | 2025-11-14 | |
| No filing history on record for this holder in this stock. | ||||||